Standardized assessment of adverse events in rheumatology clinical trials: Summary of the OMERACT 7 Drug Safety Module update

Lassere, Marissa N. D., Johnson, Kent R., Boers, Maarten, Carlton, Kerri, Day, Richard O., de Wit, Marten, Edwards, I. Ralph, Fries, James F., Furst, Daniel E., Kirwan, John R., Tugwell, Peter S., Woodworth, Thasia G. and Brooks, Peter M. (2005) Standardized assessment of adverse events in rheumatology clinical trials: Summary of the OMERACT 7 Drug Safety Module update. Journal of Rheumatology, 32 10: 2037-2041.

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
Author Lassere, Marissa N. D.
Johnson, Kent R.
Boers, Maarten
Carlton, Kerri
Day, Richard O.
de Wit, Marten
Edwards, I. Ralph
Fries, James F.
Furst, Daniel E.
Kirwan, John R.
Tugwell, Peter S.
Woodworth, Thasia G.
Brooks, Peter M.
Title Standardized assessment of adverse events in rheumatology clinical trials: Summary of the OMERACT 7 Drug Safety Module update
Journal name Journal of Rheumatology   Check publisher's open access policy
ISSN 0315-162X
Publication date 2005-10-01
Sub-type Article (original research)
Volume 32
Issue 10
Start page 2037
End page 2041
Total pages 5
Editor Duncan A. Gordon
Yvonne Pigott
Place of publication Toronto, ON, Canada
Publisher Journal of Rheumatology Publishing
Collection year 2005
Language eng
Subject C1
Formatted abstract
A presentation, demonstration, and discussion of recently developed adverse event instruments were the topics for the OMERACT 7 Drug Safety Module. The module began with a plenary introducing the needs and challenges of adverse event ascertainment. It was followed by a review of module work from previous OMERACT meetings on a prototype coding instrument (Rheumatology Common Toxicity Criteria), then a brief description of the process behind the recently developed patient self-report and investigator report adverse event instruments. These current instruments are designed for use in controlled trials although they could be used in other settings. The instruments rely primarily on patient self-reporting using a checklist, which the investigator then folds into a parallel structured but more medically sophisticated instrument. In pilot testing, this innovative dual-use system has shown reliability and acceptability, while preserving validity. A stakeholder panel of representatives from 8 sectors followed - patient, nurse investigator, regulator, clinician scientist, industry, OMERACT, global public health/WHO, and Cochrane Collaboration - for their perspectives on the needs, challenges, and potential ways forward for adverse event ascertainment and reporting in clinical trials. At the breakout session small focus groups participated in hands-on interactive testing of one of 3 versions of the instruments, which differ in degree of comprehensiveness. Each focus group had a participatory patient with rheumatoid arthritis. At a second plenary there was group feedback by rapporteurs and presentation of results from pilot studies of iterative testing of validity, reliability, and feasibility of the instruments. During plenary discussion a frequent suggestion for improvement was to refine the process so that event ascertainment could be done entirely using the patient instrument with minimal input from the investigator at the visit, if patient-investigator agreement was high. Most found the patient checklist attractive, particularly if the patient instrument was shown to be reliable and valid. Finally, a future research agenda was discussed.
Keyword Events measurement
Randomized clinical trials
Instrument validation
Drug Tolerability Index
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 10 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 05:47:38 EST